PTC Therapeutics Inc [PTCT] stock is trading at $45.08, down -0.38%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTCT shares have gain 7.82% over the last week, with a monthly amount drifted -0.84%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $67 from $45. Previously, RBC Capital Mkts upgraded its rating to Outperform on December 03, 2024, and elevated its price target to $63. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $44 on September 04, 2024. Raymond James upgraded its rating to Mkt Perform for this stock on May 20, 2024. In a note dated December 19, 2023, Morgan Stanley downgraded an Underweight rating on this stock but restated the target price of $28.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $23.58 and $54.16 over the past year. Currently, Wall Street analysts expect the stock to reach $50.5 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $45.08 at the most recent close of the market. An investor can expect a potential return of 12.02% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 900.66M for the trailing twelve months, which represents a growth of 0.11%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 0.48 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.22 points at the first support level, and at 43.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.67, and for the 2nd resistance point, it is at 46.26.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 2.10. On the other hand, the Quick Ratio is 2.04, and the Cash Ratio is 0.86. Considering the valuation of this stock, the price to sales ratio is 3.86.
Transactions by insiders
Recent insider trading involved Utter Christine Marie, SVP, CHIEF ACCOUNTING OFFICER, that happened on Jan 08 ’25 when 1662.0 shares were sold. SVP, CHIEF ACCOUNTING OFFICER, Utter Christine Marie completed a deal on Jan 07 ’25 to sell 1291.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Pauwels Eric sold 2136.0 shares on Jan 08 ’25.
